BlossomHill Therapeutics, Inc. Stock

Stocks

Market Closed - Nasdaq 04:00:00 2026-10-15 pm EDT			5-day change	1st Jan Change
14.98 ^USD	-1.83%		-11.26%	-

Sep. 28	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
Sep. 20	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI

NasdaqUSD

Markets		Quality
Nasdaq	BLSM	Delayed
CBOE	BLSM	Real-time

Sep. 28	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
Sep. 20	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI
Sep. 18	BlossomHill Therapeutics Q2 Loss Widens	MT
Sep. 18	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT
Sep. 18	BlossomHill Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Sep. 15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 Solara Trial Demonstrating Anti-Tumor Activity of Omni-EGFR Inhibitor BH-30643 in EGFR C797s-Positive NSCLC	CI
Sep. 15	BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial	MT
Sep. 01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
Sep. 01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
Sep. 01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
Sep. 01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT
Aug. 18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
Aug. 18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI

Sep. 01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
Sep. 01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
Sep. 01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
Sep. 01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT

Sep. 28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	GL
Sep. 28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	AQ
Sep. 18	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results	GL
Sep. 15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer	GL
Sep. 03	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference	GL

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	2020-05-31
Jason Keyes DFI	Director of Finance/CFO	55	2025-04-30
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	2020-05-31
Bihua Chen BRD	Director/Board Member	57	2021-01-31
Yi Shan Li CHM	Chairman	61	2020-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/10/26	Sundeep Agrawal	Conversion	Director	1,157,048	3.6917%
8/10/26	Cormorant Asset Management LP	Conversion	Company	6,915,568	22.0651%
8/10/26	Vincent Liptak	Buy	General Counsel	47,574	0.1518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	-1.83%	-11.26%	-	-	485M
WUXI APPTEC CO., LTD.	+0.21%	-4.63%	+55.34%	+71.32%	68.92B
ARGENX SE	+1.66%	+7.51%	+8.12%	+60.04%	51.9B
LONZA GROUP AG	+3.14%	+7.17%	+12.48%	+44.42%	48.73B
IQVIA HOLDINGS INC.	+3.45%	+4.70%	+33.44%	+35.96%	43.13B
REVOLUTION MEDICINES, INC.	-2.20%	+0.61%	+281.88%	+532.76%	41.48B
BEONE MEDICINES AG	+6.43%	+6.84%	+18.32%	+109.23%	39.96B
CELLTRION, INC.	+1.28%	+1.39%	+11.69%	+45.10%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	+3.31%	-6.69%	+37.07%	+2.55%	26.01B
BIONTECH SE	+1.74%	-2.02%	-13.55%	-12.92%	22.27B
Average	+1.72%	-1.97%	+49.42%	+98.72%	37.35B
Weighted average by Cap.	+1.96%	-0.26%	+52.90%	+105.55%